Product Program year 2025 Source: CMS Open Payments

Duopa

Drug Neuroscience

NDC 0074-3012-07

Open in the dashboard

General payments

$3,574,906

32,074 payments

Research payments

$623,895

166 payments

Through program year 2025, $3,574,906 in general payments and $623,895 in research payments were reported against Duopa (Neuroscience).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

12 rows
Year Kind Amount Payments
2025 General $6,795 86
2024 General $320,090 5,875
2024 Research $4,703 2
2023 General $586,297 7,909
2022 General $556,343 6,518
2022 Research $6,516 3
2021 General $697,658 5,771
2021 Research $98,021 24
2020 General $393,827 1,797
2020 Research $192,251 59
2019 General $1,013,897 4,118
2019 Research $322,404 78

Breakdown

Who paid General payments · program years 2019–2025
  1. AbbVie, Inc. $3,574,906 32,074 payments
Top recipients General payments · program year 2025
  1. Jennifer Chen Neurology · New Brunswick, NJ $135 2% · 1 payment
  2. Gabriel Vazquez Velez Neurology · Saint Louis, MO $135 2% · 1 payment
  3. Sandra Antigua Jimenez Neurology · Omaha, NE $135 2% · 1 payment
  4. Shannon Doerhoff Nurse Practitioner, Acute Care · Little Rock, AR $135 2% · 1 payment
  5. Lindsey Armston Nurse Practitioner · Chula Vista, CA $135 2% · 1 payment

The top 5 of 83 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Neurology Psychiatry & Neurology $4,318 71% · 49 practitioners
  2. Nurse Practitioner $337 6% · 5 practitioners
  3. Nurse Practitioner, Gerontology Nurse Practitioner $272 4% · 3 practitioners
  4. Nurse Practitioner, Family Nurse Practitioner $269 4% · 2 practitioners
  5. Physician Assistant $267 4% · 3 practitioners

The top 5 of 16 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Virginia $1,664 24% · 14 recipients
  2. California $942 14% · 7 recipients
  3. Michigan $394 6% · 9 recipients
  4. Florida $364 5% · 7 recipients
  5. Illinois $302 4% · 3 recipients

The top 5 of 26 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

254

Prescriptions dispensed, refills included

Drug cost

$1,780,612

Paid at the pharmacy, in all

Prescribers

19

With 11 or more claims of it

Medicare Part D drugs matched to DUOPA, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Duopa Carbidopa/Levodopa Same name 19 254 $1,780,612

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 19 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Andrea Deleo Neurology IN 25 $146,771 $52
Christopher Tolleson Neurology TN 16 $97,169 $165
Amar Patel Neurology CT 15 $91,312 None on record
Shadi Barbu Neurology AZ 15 $89,936 $58
Matthew Barabas Physician Assistant NC 14 $83,927 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See all 19 in the dashboard with a free account
32,074 general · 166 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record